Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


11 Items
Title  Creator  Group name  Publishing year 
Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features Boissière-Michot et al. EquipeCTCS 2024
Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer Mirandola et al. EquipeMY 2024-09-19
Inferring ligand-receptor cellular networks from bulk and spatial transcriptomic datasets with BulkSignalR Villemin et al. EquipeMY 2023-05-05
BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib Velazquez et al. EquipeMY 2023
A straightforward method to quantify circulating mRNAs as biomarkers of colorectal cancer Grosgeorges et al. EquipeMY 2023-02-15
Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy Neron et al. EquipeAT 2022-04-19
In situ hybridization for the assessment of urokinase plasminogen activator and plasminogen activator inhibitor type?1 in formalin?fixed paraffin?embedded breast cancer specimens Boissière-Michot et al. EquipeCTCS 2022-06
Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers Guiu et al. EquipeELC Jul 2018
Reproductive Decision-Making in MMR Mutation Carriers After Results Disclosure: Impact of Psychological Status in Childbearing Options Duffour et al. EquipeMY 06 2016
Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care El Messaoudi et al. EquipeCTCS 06 15, 2016
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial Assenat et al. EquipeCG May 20, 2015
11 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés